“…Indeed, mutations in chromatin remodeler Chd7 and histone acetyltransferase Kat6a/b are associated with birth defects leading to Charge and Ohdo syndromes, respectively (Vissers et al, 2004) (Campeau et al, 2012). KMT2D, also known as MLL2 methylates histone 3 at lysine 4 (H3K4) which is associated with transcriptional repression, and KDM6A, demethylates histone 3 at lysine 27 (H3K27), mostly associated with transcriptional actiation (Ali, Hom, Blakeslee, Ikenouye, & Kutateladze, 2014;Hong et al, 2007;Koutsioumpa et al, 2019;Lan et al, 2007), both genes are frequently mutated in patients with Kabuki Syndrome (Cocciadiferro et al, 2018;Gazova, Lengeling, & Summers, 2019;Luperchio, Applegate, Bodamer, & Bjornsson, 2019;Shangguan et al, 2019;Tekendo-Ngongang, Kruszka, Martinez, & Muenke, 2019;Yap et al, 2020) (Ang et al, 2016;Schwenty-Lara, Nurnberger, & Borchers, 2019;Serrano, Demarest, Tone-Pah-Hote, Tristani-Firouzi, & Yost, 2019). KMT2D or lysine-specific methyltransferase 2D, is also known as MLL2 or myeloid/lymphoid or mixed-lineage leukemia 2.…”